The trial enrolled 531 adult subjects with multiple myeloma who had received at least one previous line of therapy.

French drug major Sanofi (SNY) announced Monday that its Sarclisa has obtained first approval in China for the treatment of adult ...

Sanofi SA (NASDAQ:SNY) released results from the IRAKLIA phase 3 study evaluating the non-inferiority of Sarclisa (isatuximab ...

Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma Approval based on positive pivotal ICARIA-MM phase 3 study using the China-bas ...

Sanofi (SNY) reported positive results from a Phase 3 study of its new subcutaneous formulation of Sarclisa in the treatment ...

China NMPA approves Sanofi’s Sarclisa in combo with pomalidomide and dexamethasone to treat adult patients with R/R multiple myeloma: Paris Tuesday, January 14, 2025, 10:00 Hrs ...

The National Medical Products Administration (NMPA) in China has approved Sarclisa, an anti-CD38 medicine, in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients ...

Sanofi continues to advance Sarclisa as part of a patient ... as select hematologic malignancies and solid tumours with critical unmet needs, including multiple myeloma, acute myeloid leukaemia, ...

If the subcutaneous delivery method gains approval, an advantage daratumumab holds over isatuximab would be removed.